Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
10 Hints for an Effective New employee screening - 2Step by step instructions to Protect Your Senior Condo for Ideal Wellbeing and Solace
- 3RFK Jr.'s vaccine panel delays hepatitis B shot vote after chaotic meeting
- 49 African migrants died in freezing temperatures near Morocco-Algeria border
- 5Safeguarding Your Senior Protection Against Extortion and Tricks.
- Israel kidnaps PIJ terrorist in covert op. in Hamas-controlled Gaza in pursuit of Ran Gvili
- The most effective method to Integrate Compact disc Rates into Your Retirement Arranging
- The Way to Fruitful Weight reduction: Individual Wellbeing Excursions
- Find the Standards of Viable Nurturing: Supporting Blissful and Strong Kids
- Figure out How to Explore Your Direction to the Best Dental Embed Trained professional: A Far reaching Manual
- My Enterprising Excursion: Building a Startup
- Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns
- Climbing Mount Everest: An Individual Victory
- CVS forecasts 2026 profit above estimates on strong performance
